Tobacco use knowledge summaries: tobacco use and dementia. by unknown
▪	 Smoking is a risk factor for dementia, and quitting could reduce the dementia burden.  
▪	 Second-hand smoke exposure may also increase the risk of dementia.
▪	 14% of Alzheimer’s disease cases worldwide are potentially attributed to smoking.
▪	 As no treatments are currently available to cure or alter the progressive course of dementia, it is  
essential to identify modifiable risk factors for reducing the occurrence of the disease, delaying its onset 
or reducing its burden.
▪	 Governments should actively implement and enforce the measures of the WHO Framework Convention 
on Tobacco Control, especially smoke-free environment laws and systematic access to tobacco cessation 
services. 
some because of the substantial cost of medical, social and 
informal care due to the dependency and disabling character-
istics of the condition. The average global annual cost of care 
for a person with dementia is US$ 17 000. However this cost 
varies drastically by country – ranging from US$ 868 in low-
income countries, to US$ 3109 in lower-middle income coun-
tries, US$ 6827 in upper-middle income countries and US$ 32 
865 in high-income countries (6).
In 2010, worldwide costs of dementia were estimated as being 
approximately US$ 604 billion (1). Direct medical costs make 
up the smallest portion of cost, comprising 16% of the global 
cost of dementia. In HICs, informal social care (family mem-
bers, friends etc.) and formal social care (nursing home, care 
facilities etc.) account for the majority of the costs (45% and 
40% respectively). In LMICs, informal social care accounts for 
the majority (almost 60%) of economic costs. In the coming 
decades, changing population demographics in LMICs is likely 
to see a reduction in the availability of extended family mem-
bers for informal social care thus increasing the proportion of 
direct social care and subsequently the economic burden of 
dementia (1).  
Currently, there are no treatments available to cure or alter 
the progressive course of dementia, although clinical trials are 
underway (1). Until effective treatments are identified, strate-
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What is dementia? 
Dementia is a syndrome resulting from disease of the brain, 
usually of a chronic or progressive nature; it involves a decline 
in thinking beyond what is normally expected from ageing, 
and may affect memory, thinking, orientation, comprehen-
sion, calculation, learning capacity, language, and judgement. 
Consciousness is not clouded (1). The impairments of cogni-
tive function are commonly accompanied, and occasionally 
preceded, by deterioration in emotional control, social be-
haviour, or motivation. This syndrome occurs in Alzheimer’s 
disease (AD), in cerebrovascular disease (CeVD), and in other 
conditions primarily or secondarily affecting the brain (1). De-
mentia is most likely the consequence of interactions between 
genetic, environmental, and lifestyle factors (2).
Alzheimer’s disease is a degenerative cerebral disease of un-
known etiology with characteristic neuropathological and 
neurochemical features. AD-related dementia onset is usually 
subtle and progresses slowly over a period of several years; 
episodic memory is one of the first cognitive domains to be af-
fected (3). 
Cerebrovascular Disease refers to the full spectrum of small- 
and large-vessel vascular pathology in the brain and is highly 
prevalent in older individuals. Smoking and hypertension are 
major risk factors for CeVD (4).
Vascular dementia (VaD) is linked to CeVD, especially following 
brain infarcts. Clinical onset typically features impaired frontal-
executive function and slowed processing speed (5).
The problem
Approximately 7.7 million new cases of dementia are identi-
fied every year – i.e. a new case identified every 4 seconds (1). 
Dementia, whose prevalence increases with age, is the lead-
ing cause of dependency and disability among older people 
in both high-income countries (HICs) and low- and middle-
income countries (LMICs). In 2010, approximately 36 million 
adults globally were living with dementia (1).
The combined effects of an ageing global population and the 
increased risk of dementia with advanced age will dramatically 
increase the global prevalence of dementia over the next 40 
years (1). It is estimated that by 2050, some 2 billion people 
worldwide will be over the age of 60, and the number of peo-
ple living with dementia is expected to reach 115 million. This 
increase is predicted to be especially rapid in LMICs (1).
Dementia is emotionally demanding for patients and caregiv-
ers as it can cause severe behavioural and psychological symp-
toms in the patient. Dementia is also economically burden-
Tobacco definitions 
Smoked tobacco product: any product made or 
derived from tobacco that is intended for human 
consumption. Examples include manufactured 
cigarettes, roll-your-own tobacco, cigars, shisha, 
kreteks and bidis.  
Smokeless tobacco: any product that consists of 
cut, ground, powdered, or leaf tobacco and that 
is intended to be placed in the oral or nasal cavity. 
Examples include gutka, mishri, and snus. 
Second-hand smoke (SHS): the combination of 
“mainstream” smoke exhaled by the smoker, and 
“side-stream” smoke emitted into the environ-
ment from lit cigarettes and other smoked to-
bacco products. The terms “passive smoking” or 
“involuntary smoking” are also often used to de-
scribe exposure to SHS.
gies for reducing the occurrence of the disease, or delay its 
onset and lessen the burden must rely on identifying and tak-
ing action upon modifiable risk factors (1 
Whilst individual genetic make-up, age and family history can-
not be changed, acting on modifiable risk factors may reduce 
the risk of dementia at both individual and population levels 
(2).  The modifiable risk factors for dementia include tobacco 
smoking, physical inactivity, hypertension, obesity, diabetes, 
and low levels of cognitive activity or low educational attain-
ment (7). This document aims to summarise the published 
links between tobacco use (smoking and smokeless) and ex-
posure to secondhand smoke and dementia. 
Pathophysiology of tobacco use 
in dementia
Smoking tobacco is hypothesized to cause dementia via sev-
eral mechanisms (see Figure 1). The most recognized causal 
pathway is via vascular risk factors that may ultimately cause 
cerebrovascular disease, stroke and coronary heart disease 
(8–10). Smoking increases total plasma homocysteine, an in-
dependent risk factor for stroke, cognitive impairment, AD and 
other dementias (11– 14). Smoking also accelerates athero-
sclerosis, causing a narrowing of blood vessels in the heart and 
brain that can deprive brain cells of proper oxygen, nutrient 
and by-product exchange (15). Finally, smoking can cause oxi-
dative stress, which is associated with excitotoxicity, leading 
to neural death (16). Oxidative stress is also associated with 
an inflammatory response that may be directly or indirectly 
related to the neuropathology of AD (17–18). Apolipoprotein 
E (APOE) ε4 allele, is a genetic risk factor for dementia, and 
smoking tobacco can increase the risk for carriers of this gene 
(19–20).
The pathophysiological link between second-hand smoke 
(SHS) exposure and dementia is not well understood. At this 
time, an indirect causal pathway is biologically plausible be-
cause of recognized associations between SHS exposure, in-
creased risk of cardiovascular conditions and stroke (21–22). 
The cardiovascular effects of second-hand smoke are nearly 
as great as for smoking, and operate through essentially the 
same biological mechanisms as described earlier (23–25). 
Even less is known about the effects of smokeless tobacco use 
on dementia. Smokeless tobacco contains over 2000 chemical 
compounds, including nicotine. It is biologically plausible that 
the use of smokeless tobacco could increase the risk of de-
mentia through cardiovascular disease-related mechanisms, 
as use of snus has an increased risk of death from cardiovas-
cular disease (26).
Tobacco smoking and dementia
There is evidence that current smoking is associated with an 
increased risk of developing dementia and AD (6, 27–36). This 
evidence was consistent across varied study settings. A meta-
analysis of studies undertaken mostly in the 1990s and early 
2000s found that relative to never smokers, current smokers 
had risks of 1.79 (95% CI 1.43–2.23) for AD and 1.78 (95%CI 
1.28–2.47) for VaD (25). Another systematic review published 
at about the same time confirmed the previous findings with 
risks of 1.59 (95% CI 1.15–2.20) for AD and 1.35 (95%CI 0.90–
2.02) for VaD (6). While these findings were mostly from high 
income countries, results of studies from low and middle in-
come countries – China, India and Latin America (Cuba, Domin-
ican Republic, Mexico, Peru, Venezuela) – have also concluded 
a heightened risk of dementia among people with a history 
of tobacco smoking (35). There is also some evidence of a 
dose-response relationship, indicating that the more someone 
smokes, the higher their risk for developing dementia (37). It is 
estimated that 14% of AD cases worldwide are potentially at-
tributable to smoking (1, 35). Past history of smoking presents 
less consistent results, possibly indicating that quitting smok-
ing later in life is still beneficial and could reduce the risk of AD 
or other forms of dementia compared with continued smoking 
(6, 27–36). 
The above findings are in contradiction with several studies 
that had previously led to an opposite conclusion, namely that 
use of tobacco was protective against dementia, particularly 
Alzheimer’s Disease (6, 34, 36).  The review of the literature 
points to two likely explanations. The first explanation is well 
summarised in the 2014 US Surgeon General Report which 
states that “… there is evidence that the tobacco industry in-
fluenced many … epidemiologic studies of smoking and psychi-
atric disorders …” (38).  Indeed a systematic review of studies 
conducted by researchers with no links to the tobacco industry 
found current smoking to be associated with a 45% higher risk 
of dementia, whereas studies undertaken by scientists with 
tobacco industry affiliations reported a 40% lower risk of de-
mentia among current smokers (34). The second additionnal 
explanation for the apparent protective value of tobacco use 
relates to study design, in particular, the use of cross-sectional 
and case control studies. There is widespread agreement in 
the literature that the use of case-control and cross-sectional 
study designs can engender multiple avenues for bias, includ-
ing selection and survival biases  (6, 34). A meta-analysis of 
cohort studies found a risk estimate of 1.99 (95% CI 1.33–2.98) 
compared with a meta-analysis of case-control studies that 
produced a pooled estimate of 0.91 (95% CI 0.53–1.27) (6). 
Additionally, recent research has shown that smokers with de-
mentia are more likely to die earlier than non-smokers with 
dementia (38). 
 The literature search did not find any systematic reviews or 
studies which examined the impact of current or past tobacco 
smoking on risk of early onset dementia, or on the prognosis 
of AD or other forms of dementia. However, given the benefits 
that accrue to former smokers relative to current smokers for 
many other conditions, it is not inconceivable that brain health 
benefits could also accrue to former smokers.
Smokeless tobacco and dementia
No systematic reviews have been published on the association 
between the use of smokeless tobacco and AD or any other 
form of dementia. One population-based cross-sectional study 
in India evaluated this association and concluded there was 
not a significant association between smokeless tobacco use 
and risk of dementia (39).
Second-hand smoke and dementia
At the time of publication no systematic reviews were available 
on SHS exposure and dementia. However, four publications 
from two studies have suggested an increased risk of AD or 
other forms of dementia among those exposed to SHS. These 
studies also found a dose-response relationship between SHS 
exposure and risk of dementia or AD (39–41). 
Three publications from a large-scale population-based cross-
sectional survey in Anhui, China linked SHS exposure with 
risk of dementia in the general population and among never-
smokers (36, 37, 41). These studies also showed that risk of 
dementia increased with duration and level of exposure. Expo-
sure to SHS at any location (e.g. home or work) increased the 
risk for all dementias by 78% (RR 1.78, 95% CI 1.18–2.68). The 
association was strongest for exposure in the home. 
Two studies looking at risk of dementia among never-smokers 
concluded the risk of AD-related dementia from SHS expo-
sure is associated with location and duration of exposure. The 
highest SHS risk from exposure in a single location was in the 
home (RR 2.15, 95% CI 1.69–2.74), followed by work (RR 2.04, 
95% CI 1.72–2.42), and finally other places (RR 1.80, 95% CI 
0.96–3.38). The greatest risk for dementia was found follow-
ing exposure in all three locations (adjusted RR 2.28, 95% CI 
1.82–2.84) (40). 
A study evaluating dementia severity prior to diagnosis con-
cluded that exposure to SHS significantly increased the risk for 
severe dementia syndromes (adjusted RR 1.29, 95% CI 1.05–
1.59), and this was related to duration and frequency of expo-
sure to SHS in a dose-dependent manner (41). 
Next steps
Although there is relatively strong evidence in the literature of 
a link between current cigarette smoking and risk of dementia, 
more well-designed long-term prospective rather than ret-
rospective case-control studies are needed to address smok-
ing and smokeless tobacco products, as well as exposure to 
second-hand smoke. Also, more research is needed as to the 
timing of smoking cessation in the lifespan and subsequent 
normalization of dementia risk. Finally, there is a need for 
population-based prospective studies that quantitatively mea-
sure biomarkers of SHS exposure to more rigorously assess its 
etiological role in the development of dementia.
Population level actions
AD, VaD and other forms of dementia place a huge health and 
socioeconomic burden on individuals, families and communi-
ties, in addition to tobacco-related stroke, cardiovascular and 
cancer burden. Reducing tobacco use and exposure to second-
hand smoke are therefore key areas of action. With recent re-
search demonstrating the effectiveness of smoke-free legisla-
tion for protecting the health of non-smokers, governments 
should continue to incorporate the measures relating to cre-
ate smoke-free environments laid out in the WHO Framework 
Convention on Tobacco Control (WHO FCTC) (42). This effort 
should also include regulatory reforms and increasing public 
awareness of the risk of tobacco-caused dementia. Recom-
mended actions include: the creation of smoke-free public 
places and workplaces; ensuring the availability of tobacco-
cessation services (including tobacco quit lines and the in-
tegration of brief advice into the health system at all levels); 
health-warning labelling of tobacco products to include the 
risk of dementia; mass-media campaigns; plain packaging of 
tobacco products (as has been recently introduced in Aus-
tralia); establishing and enforcing bans on tobacco advertis-
ing, promotion and sponsorship; and raising taxes on tobacco 
products. 
Individual level action
Given that, at present, no treatments are available to cure or 
alter the progressive course of dementia, it is essential to iden-
tify modifiable risk factors for reducing the occurrence of the 
disease, delaying its onset or reducing its burden (1). Quitting 
tobacco use (and controlling other risk factors) could help re-
duce the risk of cardiovascular diseases and dementia, and en-
couraging and supporting current tobacco users to quit should 
be a top priority for prevention of dementia and AD. Dementia 
should be added in all educational materials that address the 
harmful effects of smoking. Clinicians, such as neurologists, 
psychiatrists, geriatricians and family practitioners should rou-
tinely advise their patients about quitting or avoiding tobacco 
exposure, and about controlling other risk factors. Non-smok-
ers should demand smoke-free legislation and make their 
homes, workplaces and other places they visit smoke-free.
Information and advice on quitting tobacco use can be found 
through the following:
▪	 www.smokefree.gov
▪	  Quitlines/Helplines 
▪	  WHO package of essential noncommunicable 
(PEN) disease interventions http://www.who.int/
cardiovascular_diseases/publications/pen2010/
en/
Further information
▪	  WHO 2012 Dementia – A Public Health Priority: 
http://www.who.int/mental_health
▪	  WHO Tobacco Free Initiative (TFI): http://www.
who.int/tobacco/en/
▪	 WHO FCTC: http://www.who.int/fctc/en/
▪	 Alzheimer’s disease International: http://www.
alz.co.uk/ 
Method
WHO conducted a comprehensive literature review that, in 
the first instance searched for all systematic reviews that stud-
ied smoked, smokeless tobacco, and second-hand smoke and 
AD and other forms of dementia. The search then focused 
on identifying as many peer reviewed articles as possible. Al-
though the search focussed on papers published since 2007, 
the reviews themselves included articles that spanned the pe-
riod since the mid-1990s. The inclusion criteria included a hu-
man study population, a dementia outcome, and tobacco use 
or exposure at any time over the life course. The review was 
not limited to any particular study design or language, how-
ever very few non-English language studies or reports were 
identified. 
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warranty	of	any	kind,	either	expressed	or	implied.	The	responsibility	for	the	interpretation	and	use	of	the	material	lies	with	the	reader.	In	no	event	shall	the	World	Health	Organization	be	liable	for	
damages	arising	from	its	use.		
The	named	authors	alone	are	responsible	for	the	views	expressed	in	this	publication.
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